Estimates Revisions Unicycive Therapeutics, Inc.

Stocks

Real-time Estimate Cboe BZX 03:59:52 19/09/2026 HKT			5-day change	1st Jan Change
4.820 ^USD	+1.05%		-9.64%	-17.16%

08-13	B. Riley Adjusts Price Target on Unicycive Therapeutics to $20 From $22, Maintains Buy Rating	MT
08-12	Unicycive Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	1y. Revenue rev.	1y. EPS revision
	UNICYCIVE THERAPEUTICS, INC.
	WUXI APPTEC CO., LTD.
	ARGENX SE
	INSMED INCORPORATED
	BIONTECH SE
	GENMAB A/S
	PHARMAESSENTIA CORPORATION
	EXELIXIS, INC.
	SUMMIT THERAPEUTICS INC.
	MADRIGAL PHARMACEUTICALS, INC.
	Average
	Weighted average by Cap.